Screener / SEC EDGAR /CIK 0000914156 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Instruments

UFP Technologies Inc UFPT

The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. 10-K, Item 1

Employees
4,846
Headquarters
Newburyport, MA
CEO
R. Jeffrey Bailly
Next results
around Feb 23, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $602.8M through the costs to a net profit of $68.3M · income statement of the 10-K

15% operating margin
Revenue to Gross profit: $170.4MRevenue to Cost of revenue: $432.4MGross profit to Operating profit: $92.3MGross profit to Operating expenses: $78.1MOperating profit to Net profit: $68.3MOperating profit to Tax & other: $24.0MOperating expenses to R&D: $8.6MOperating expenses to Sales, admin & other: $69.5M Revenue: $602.8M REVENUE $602.8M +20% Y/Y Gross profit: $170.4M · 28% margin GROSS PROFIT $170.4M 28% margin · +16% Y/Y Cost of revenue: $432.4M · 72% of revenue COST OF REVENUE $432.4M 72% of revenue Operating profit: $92.3M · 15% margin OPERATING PROFIT $92.3M 15% margin · +14% Y/Y Operating expenses: $78.1M · 13% of revenue OPERATING EXPENSES $78.1M 13% of revenue Net profit: $68.3M · 11% margin NET PROFIT $68.3M 11% margin · +16% Y/Y Tax & other: $24.0M · 4% of revenue TAX & OTHER $24.0M 4% of revenue R&D: $8.6M · 1% of revenue R&D $8.6M 1% of revenue Sales, admin & other: $69.5M · 12% of revenue SALES, ADMIN & OTHER $69.5M 12% of revenue
Gross profit $170.4M 28% margin · +16% Y/Y
Operating profit $92.3M 15% margin · +14% Y/Y
Net profit $68.3M 11% margin · +16% Y/Y
The full income statement, year by year

UFPT among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 19.5%, above 73% of 154 peers (their median 10.4%) REVENUE GROWTH 19.5% · above 73% Gross margin: 28.9%, above 11% of 107 peers (their median 63.8%) GROSS MARGIN 28.9% · above 11% Operating margin: 15.5%, above 70% of 138 peers (their median 9.8%) OPERATING MARGIN 15.5% · above 70% Net margin: 11.8%, above 64% of 153 peers (their median 6.7%) NET MARGIN 11.8% · above 64% Return on capital: 13.1%, above 76% of 89 peers (their median 9.0%) RETURN ON CAPITAL 13.1% · above 76%
UFPT Peer median Below the median

What changed

35 new risk paragraphs. 10-K filed Feb 27, 2026 against Mar 3, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Receivables -2.1% ($84.7M to $82.9M) vs revenue +19.5% ($504.4M to $602.8M), -21.6 pts apart
  • Cash from operations $91.9M vs net income $68.3M (FY ending Dec 31, 2025)
  • Inventory -0.8% ($87.5M to $86.9M) vs revenue +19.5% ($504.4M to $602.8M), -20.3 pts apart
7 more checks with nothing to note
  • Same auditor in both 10-Ks: GRANT THORNTON LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

35 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.

All 35 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Our operating results depend in part on our ability to contain or reduce costs. There is substantial price competition in our industry and upward pressure on material and labor costs. Our success and profitability will depend on our ability to maintain a competitive cost and price structure. Our efforts to maintain and improve…
  2. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Based on customer specifications, we are continuously developing new products and improving existing products. Our existing and newly introduced products can contain undetected errors or defects. In addition, these products may not meet
  3. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements may adversely impact our business and financial results. Laws and regulations in various countries around the world with regards to cybersecurity, privacy and data protection are rapidly…
  4. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Even the most well protected IT networks, systems and facilities remain potentially vulnerable because the techniques used in attempted cybersecurity attacks are continually evolving, and may not be recognized until after the attack is launched against a target or, in some instances, are designed not to be detected and, in fact, may not…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$353.8M$400.1M$504.4M$602.8M
Net income$41.8M$44.9M$59.0M$68.3M
Operating cash flow$17.7M$41.3M$66.6M$91.9M
Free cash flow$4.0M$30.8M$56.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$602.8M ▲ 19.5% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

UFP Technologies Inc, Newburyport, MA · from the 10-K filed Feb 27, 2026

The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.

Headquarters
Newburyport, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Employees, at the top of the page: "As of January 24, 2026, the Company had a total of 4,846 full-time employees (compared to 4,146 full-time employees as of January 25, 2025) and 503 temporary workers (compared to 189 temporary workers at January 25, 2025)" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UFPT/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.